Catalyst

The Clinical and Translational Science Institute (CTSI) at UC San Francisco (UCSF), a unit within the Office of Research, will support, coordinate and respond to COVID-19 research needs. Some of CTSI’s efforts to support impactful COVID-19 research include:

Note: Shuvo Roy, PhD, is a four-time CTSI Catalyst Program Awardee, for different applications of his silicon membrane technology including for the kidney, artificial pancreas and high efficiency external ambulatory lung.

Note: The Blackstone LaunchPad hub at UCSF will be administered by CTSI's Catalyst Program.

Note: Charles Chiu, MD, PhD, senior author, is a 2014 UC CAI NHLBI Award recipient. The UC CAI program at UCSF is administered and project managed through CTSI's Catalyst program. His project that received UC CAI funding was a rapid unbiased assay for detection of pneumonia - this technique of unbiased next generation sequencing has been used for his other research mentioned in the article.

Note: Hideho Okada, MD, PhD, was a Fall 2015 Catalyst Awardee. His project, "Novel Mutation-derived Neoantigen for T Cell Therapy in Gliomas" is now being out-licensed to the immuno-oncology company, Tmunity.

Note: Robert Blelloch, MD, PhD, professor of urology received a Catalyst award in Spring 2018 for the development of small molecule inhibitors of immune checkpoint protein presentation. This included an award and consultation - the Catalyst program team is excited to see the project's progress.

Note: The New York Times has published an article featuring the research of Catalyst Awardee and UCSF Professor Dena Dubal, MD, PhD. Dr. Dubal's research investigates the hormone Klotho in potential treatments for dementia and other aging disorders. Dr. Dubal's Fall 2016 Catalyst Award titled, "Brain Resilience: A New Approach for Treating Neurodegenerative Diseases" supported this research through funding and consultations.

One Day There May Be a Drug to Turbocharge the Brain. Who Should Get It?

Note: CTSI's Catalyst Awards program supported this research by Pamela England during her participation in the Spring 2014 cycle.

Successful Pharmacological Activation of Nurr1 Opens Doors to Novel Therapies for Incurable Movement Disorder

By Nicholas Weiler via UCSF.edu

Note: Charles Craik, PhD, three-time Catalyst Program awardee (Spring 2018, Fall 2016, Spring 2012) shares his insights on intellectual property with the American Society for Biochemistry and Molecular Biology.

By Laurel Oldach via ASBMB Today

Charles Craik knows a lot about patenting research findings.